DUBLIN--(BUSINESS WIRE)--The "Chronic Inducible Urticaria Market Insights, Epidemiology, and Market Forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.
This report, delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of Chronic Inducible Urticaria (CIndU) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The Chronic Inducible Urticaria (CIndU) market report provides analysis regarding current treatment practices, emerging drugs like AK002, potential therapies, market share of the individual therapies, and historical, current and forecasted CIndU market size from 2017 to 2030, segmented by seven major markets.
The report also covers current Chronic Inducible Urticaria treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess the underlying potential of the market.
Management of CIndU typically involves threshold testing and consecutive avoidance of relevant triggers. Where this is not possible or feasible, symptomatic treatment follows a stepwise approach, starting with a standard dose of non-sedating H1-antihistamines. Dosing can be increased up to four-fold, which represents an off-label use because patients with CIndU can benefit from up dosing.
This chapter covers the details of conventional and current medical therapies available for the treatment of CIndU. It also provides the country-wise CIndU treatment guidelines across the United States, Europe and Japan.
The Chronic Inducible Urticaria market report gives a thorough understanding of the disease by including details such as disease definition, symptoms, types, grading, pathophysiology, and diagnosis. It also provides CIndU treatment algorithms and treatment guidelines in the US, Europe, and Japan.
The Chronic Inducible Urticaria (CIndU) epidemiology chapters provide insights about historical and current CIndU patient pool and forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. CIndU epidemiology is segmented by the diagnosed prevalent cases of CU, diagnosed prevalent cases of CIndU, prevalence of chronic inducible urticaria by types. Besides, the report includes a thorough analysis of all segments.
It has been observed that about 50% cases of CIndU are symptomatic dermographism and 20% each are cold urticaria and cholinergic urticaria; the other 10% are the other forms of CIndU.
According to the publisher's, the total prevalent population of CIndU in seven major markets was 652,542 in 2017. These cases are expected to increase with a significant CAGR during the study period (2017-2030).
Among all the seven major markets, total prevalent cases for Chronic Inducible Urticaria were highest in the United States, followed by Germany and France. Spain accounted for the least number of prevalent cases among the 7MM.
This segment encloses the detailed analysis of the drugs in the Chronic Inducible Urticaria (CIndU) pipeline. It also helps to understand the CIndU clinical trial details, expressive pharmacological action, agreements of the included drug, and the latest news and press releases.
The therapeutic goal of CIndU management primarily focusses on achieving complete symptom control, by trigger avoidance, desensitization, blocking the effects of mast cell mediators (non-sedating, second-generation antihistamines), and prevention of mast cell degranulation. Currently, there is no approved therapy for the treatment of CIndU apart from symptomatic management. The pipeline scenario does not represent a particularly close picture with only one major player making major inroads in the largely untapped market to date. AK002 (Antolimab) being developed by Allakos Pharma is the only candidate with the potential to enter the arena during the forecast period and has completed Phase II trials.
The market size of Chronic Inducible Urticaria(CIndU) is expected to increase at a significant CAGR during the study period (2017-2030). Among all the seven major markets, the United States accounted for the largest CIndU market size. Among EU5 countries, Germany had the largest market size, with USD 172 million in 2017, while Spain had the smallest market size of CIndU, with USD 104.5 million in 2017.
This section focuses on the rate of uptake of the potential drugs in the Chronic Inducible Urticaria (CIndU) market or expected to get launched in the market during the study period 2017-2030. The analysis covers CIndU market uptake by drugs; patient uptake by therapies; and sale of each drug.
It helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size. All of which will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The dynamics of CIndU market is anticipated to experience a positive shift in the coming years owing to the expected launch of AK002 (Allakos) during the forecasted period 2020-2030.
- In the coming years, the Chronic Inducible Urticaria market scenario is not expected to alter much across the 7MM due to lack of approved treatment options and a static pipeline. Lack of adequate research and development activities funded by major pharma players is also making an impact on the overall landscape.
- Our in-depth analysis of the pipeline assets across different stages of development (Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities
- Allakos Inc.
- Celldex Therapeutics
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/mfu45u